The effect of high‐dose methotrexate on renal tubules as indicated by urinary lysozyme concentration
暂无分享,去创建一个
[1] J. Herson,et al. Evaluation of overall toxicity of high-dosage methotrexate regimens. , 1979, Medical and pediatric oncology.
[2] T. Lehner,et al. Immunological aspects of recurrent oral ulceration and Behçet's syndrome. , 1978, Journal of oral pathology.
[3] J. Legros. Urinary excretion of neurophysins in patients with kidney disease. , 1978, The Journal of endocrinology.
[4] G. Neale,et al. Serum and faecal lysozyme in inflammatory bowel disease. , 1978, Gut.
[5] Jerome J. Schentag,et al. Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin. , 1978, Journal of medicine.
[6] M. Irving,et al. Methotrexate megadose followed by folate rescue. II. Clearance patterns in patients receiving sequential megadose infusions. , 1976, The Medical journal of Australia.
[7] D. Lovell,et al. Renal damage caused by gentamicin: A study of the effects on renal morphology and urinary enzyme excretion , 1976, The Journal of pathology.
[8] B. Chabner,et al. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. , 1976, The Journal of clinical investigation.
[9] A. Evan,et al. The effects of sodium chromate on the proximal tubules of the rat kidney. Fine structural damage and lysozymuria. , 1974, Laboratory investigation; a journal of technical methods and pathology.
[10] J. Wauters,et al. [Urine lysozyme determination as a diagnostic tool in nephropathies]. , 1970, Schweizerische medizinische Wochenschrift.
[11] H. Baker. Some hazards of methotrexate treatment of psoriasis. , 1970, Transactions of the St. John's Hospital Dermatological Society.
[12] R G Adams,et al. The development of cadmium-induced proteinuria, impaired renal function, and osteomalacia in alkaline battery workers. , 1969, The Quarterly journal of medicine.
[13] F. Morgenthaler,et al. Methotrexate excretion patterns and renal toxicity after intravenous injection or arterial infusion. , 1969, Archives of surgery.
[14] T. Ryan,et al. SYSTEMIC CONRTICOSTEROIDS AND FOLIC ACID ANATONISTS IN THE TREATMENT OF GENRALIZED PUSTULAR PSOBLASIS EVALUATION AND PROGNOSIS BASED ON THE STUDY OF 104 CASES , 1969, The British journal of dermatology.
[15] R. E. Chanes,et al. Renal toxicity of methotrexate , 1969, Cancer.
[16] J. Hayslett,et al. Urinary muramidase and renal disease. Correlation with renal histology and implication for the mechanism of enzymuria. , 1968, The New England journal of medicine.
[17] J. Blainey,et al. Urinary lysozyme, ribonuclease, and low-molecular-weight protein in renal disease. , 1968, Lancet.
[18] S. Finch,et al. Studies of Muramidase (Lysozyme) in Leukemia , 1968 .
[19] H. Fudenberg,et al. Leukocyte lysozyme activity in myelocytic leukemia. , 1967, Blood.
[20] A. Mckenzie,et al. The Editor, ‘The British Journal of Dermatology’. Psoriasis and folic acid antagonists. , 1967 .
[21] H. R. Vickers,et al. Psoriasis and folic acid antagonists , 1966 .
[22] E. Osserman,et al. SERUM AND URINARY LYSOZYME (MURAMIDASE) IN MONOCYTIC AND MONOMYELOCYTIC LEUKEMIA , 1966, The Journal of experimental medicine.
[23] D. Prockop,et al. A STUDY OF URINARY AND SERUM LYSOZYME IN PATIENTS WITH RENAL DISEASE. , 1964, The New England journal of medicine.
[24] G. Litwack. Photometric Determination of Lysozyme Activity.∗ † , 1955, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[25] R. Vilter. Treatment of macrocytic anemias. , 1955, A.M.A. archives of internal medicine.